Clinical trial NCT03410394: Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)
Official title: Registre Tumeurs Endocrine - Eurocrine
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Endocrine Tumor
Keywords: adrenal
thyroid
parathyroid
endocrine pancreas
endocrine digestive tube
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2018-01-25
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who undergo surgical procedures for endocrine tumors at CHU Nancy Brabois (University hospital)

Brief summary: This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.

Detailed description: The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.

Eligibility criteria: Inclusion Criteria:

* patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital

Exclusion Criteria:

* unable to receive clear information
* refusal to sign the consent form

Primary outcomes:
measure: Postoperative complications (endocrine surgical procedure)
timeFrame: 12 months after surgical procedure
Secondary outcomes:
measure: Postoperative complications severity (endocrine surgical procedure)
timeFrame: 12 months after surgical procedure
measure: Postoperative mortality (endocrine surgical procedure)
timeFrame: 12 months after surgical procedure
measure: CT imaging before endocrine surgical procedure (Tumor characteristics)
timeFrame: Baseline
measure: CT imaging before endocrine surgical procedure (Coronary artery score)
timeFrame: Baseline
measure: CT imaging before endocrine surgical procedure (Sarcopenia)
timeFrame: preoperative period
measure: Bone mineral density
timeFrame: Baseline
measure: Intraoperative systolic arterial pressure
timeFrame: Intraoperative
measure: Intraoperative diastolic arterial pressure
timeFrame: Intraoperative
measure: Parathormone plasma levels
timeFrame: Baseline and up to 12 months after surgical procedure
measure: Aldosterone plasma levels
timeFrame: Baseline and up to 12 months after surgical procedure
measure: Plasma renin activity
timeFrame: Baseline and up to 12 months after surgical procedure
measure: Plasma free metanephrines
timeFrame: Baseline and up to 12 months after surgical procedure
measure: PET scanning
timeFrame: Baseline
Other outcomes:
Locations:
city: Vandœuvre-lès-Nancy
country: France
facility: CHU Nancy
Study officials:
affiliation: University of Lorraine
name: laurent Brunaud
role: PRINCIPAL_INVESTIGATOR
References:
citation: Greilsamer T, Nomine-Criqui C, Thy M, Ullmann T, Zarnegar R, Bresler L, Brunaud L. Robotic-assisted unilateral adrenalectomy: risk factors for perioperative complications in 303 consecutive patients. Surg Endosc. 2019 Mar;33(3):802-810. doi: 10.1007/s00464-018-6346-2. Epub 2018 Jul 11.